Biopharmacopae Design International Inc., a Quebec City-based developer of plant-derived products for the skin care, cosmeceutical, and nutrition industries, has raised an undisclosed amount of Series A funding from Avrio Ventures.
Biopharmacopae Design International Inc. (“Biopharmacopae”), a company specialized in the discovery and development of innovative, science-based, plant-derived products for the skin care, cosmeceutical, and nutrition industries, today announced that it has closed a Series A round with Avrio Ventures to pursue commercialization and further product development on a suite of plant-based active ingredients and products.
Biopharmacopae will continue working with strategic partners to incorporate their unique plant-based natural active ingredients and products into leading consumer based health product offerings. Existing active ingredients and products currently exist for addressing the prevention and/or attenuation of skin aging, topical inflammation, obesity-related disorders, and viral infections.
“We are extremely pleased that Avrio Ventures has chosen to invest in Biopharmacopae. Their understanding of food technology, the nutraceutical and cosmeceutical industries, and their unique regulatory requirements, will help our company to capitalize on the multiple opportunities we see in the market,” said Dr. Johane Guay, CEO of Biopharmacopae. “There continues to be a growing demand by consumers for nutraceutical and cosmeceutical products that offer scientifically proven health benefits which are of high quality and based from non-chemical, natural ingredients. We offer our partners the innovation and proof of concept that is required to bring novel products to market efficiently.”
“Biopharmacopae’s proprietary technology, ‘eXcelerateTM’, expedites the discovery and development process for plant based bioactive extracts providing a sustainable technology platform. The company is well positioned to be a provider of a large suite of novel natural ingredients and products to its strategic partners in the natural personal care and nutraceutical industries”, commented Mr. Aki Georgacacos, Partner of Avrio Ventures. “The ability of Biopharmacopae to develop multiple new products from its vast plant library further validates the growth and innovation opportunities available in the sector.”
About Biopharmacopae Inc.
Biopharmacopae is specialized in the discovery and development of science-based innovative plant-derived active ingredients and products for the cosmeceutical and nutraceutical markets. The company owns a unique technology platform, eXcelerate™, that overcomes the traditional technical challenges associated with the discovery of health products derived from plants. www.biopharmacopae.com.
About Avrio Ventures Management Corporation
Avrio Ventures is a venture capital firm that supports the development of Canadian commercialization and growth stage industrial bio-products, nutraceutical ingredients and food technology companies into world-class organizations. www.avrioventures.com.